Cancer risk in HFE C282Y homozygotes: results from the HUNT 2 study

Abstract Objective. In addition to hepatocellular cancer, HFE C282Y homozygotes are reported to have increased risk of colorectal cancer and breast cancer. This study was done to further explore the cancer risk in C282Y homozygotes. Material and methods. We studied cancer incidence in 292 homozygotes and 62,568 others that participated in the HUNT 2 population screening in 1995–1997. Using Cox proportional hazard models, we estimated cancer hazard ratio as a function of C282Y homozygosity and several screening variables including serum transferrin saturation, alcohol consumption and daily smoking. Results. Cancer was diagnosed in 36 homozygotes, five of which had two cancer diagnoses. The overall cancer incidence was not increased in C282Y homozygotes (hazard ratio 1.10 [95% CI 0.60–2.03] in women and 0.94 [95% CI 0.53–1.66] in men). However, homozygous men had increased risk of colorectal cancer (hazard ratio 3.03 [95% CI 1.17–7.82], p = 0.022) and primary liver cancer (hazard ratio 54.0 [95% CI 2.68–1089], p = 0.009). The risk of breast cancer in homozygous women was not increased (hazard ratio 1.13 [95% CI 0.35–3.72]). Adjusted for other variables including C282Y homozygosity, very low and very high serum transferrin saturation were associated with increased overall cancer incidence. Conclusions. C282Y homozygosity is associated with increased risk of colorectal cancer and hepatocellular cancer in men. In the general population, individuals with a very low or a very high serum transferrin saturation may have increased cancer risk.

[1]  M. Espié,et al.  [Epidemiology and risk factors of breast cancer]. , 2013, Soins; la revue de reference infirmiere.

[2]  J. Barton,et al.  Increased risk of death from iron overload among 422 treated probands with HFE hemochromatosis and serum levels of ferritin greater than 1000 μg/L at diagnosis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  L. Weinehall,et al.  Iron Biomarkers in Plasma, HFE Genotypes, and the Risk for Colorectal Cancer in a Prospective Setting , 2012, Diseases of the colon and rectum.

[4]  A. Tybjærg‐Hansen,et al.  Risk of cancer by transferrin saturation levels and haemochromatosis genotype: population‐based study and meta‐analysis , 2012, Journal of internal medicine.

[5]  Manuela M. Santos,et al.  Impact of hemochromatosis gene (HFE) mutations on epithelial ovarian cancer risk and prognosis , 2011, International journal of cancer.

[6]  G. Baldwin,et al.  Gastrins, iron homeostasis and colorectal cancer. , 2011, Biochimica et biophysica acta.

[7]  Juan Luis Steegmann-Olmedillas.  The role of iron in tumour cell proliferation , 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[8]  B. Rosner,et al.  Risk factors for ductal and lobular breast cancer: results from the nurses' health study , 2010, Breast Cancer Research.

[9]  D. Gertig,et al.  HFE Cys282Tyr homozygotes with serum ferritin concentrations below 1000 μg/L are at low risk of hemochromatosis , 2010, Hepatology.

[10]  D. English,et al.  HFE C282Y homozygotes are at increased risk of breast and colorectal cancer , 2010, Hepatology.

[11]  L. Valenti,et al.  Hemochromatosis gene (HFE) mutations and cancer risk: Expanding the clinical manifestations of hereditary iron overload , 2010, Hepatology.

[12]  K. Hveem,et al.  Screening for C282Y homozygosity in a Norwegian population (HUNT2): The sensitivity and specificity of transferrin saturation , 2010, Scandinavian Journal of Clinical and Laboratory Investigation.

[13]  P. Adams.  The Natural History of Untreated HFE-Related Hemochromatosis , 2009, Acta Haematologica.

[14]  B. Nordestgaard,et al.  Hemochromatosis genotypes and risk of 31 disease endpoints: Meta‐analyses including 66,000 cases and 226,000 controls , 2007, Hepatology.

[15]  Patrick Royston,et al.  Multivariable Modeling with Cubic Regression Splines: A Principled Approach , 2007 .

[16]  K. Hveem,et al.  Persons with Screening-detected Haemochromatosis: as Healthy as the General Population? , 2002, Scandinavian journal of gastroenterology.

[17]  K. Hveem,et al.  Screening for Hemochromatosis: High Prevalence and Low Morbidity in an Unselected Population of 65,238 Persons , 2001, Scandinavian journal of gastroenterology.